MBK bids S$360m for pharmaceutical company

Private equity looks to take advantage of the refuge the pharmaceutical sector offers in uncertain economic times.

4 January 2013•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.